Last reviewed · How we verify
Ifosfamide + Mesna
Ifosfamide is an alkylating agent that cross-links DNA to kill cancer cells, while mesna is a protective agent that binds to toxic metabolites to reduce bladder toxicity.
Ifosfamide is an alkylating agent that cross-links DNA to kill cancer cells, while mesna is a protective agent that binds to toxic metabolites to reduce bladder toxicity. Used for Lymphoma (as part of combination chemotherapy regimen in phase 3 study).
At a glance
| Generic name | Ifosfamide + Mesna |
|---|---|
| Sponsor | Lymphoma Study Association |
| Drug class | Alkylating agent (with uroprotective agent) |
| Target | DNA (non-specific alkylation) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Ifosfamide works by forming covalent bonds between DNA strands, preventing replication and transcription in rapidly dividing cancer cells. Mesna is a uroprotective agent that binds to acrolein and other toxic metabolites of ifosfamide in the urine, reducing hemorrhagic cystitis and other urinary tract toxicities without compromising the anticancer activity.
Approved indications
- Lymphoma (as part of combination chemotherapy regimen in phase 3 study)
Common side effects
- Hemorrhagic cystitis
- Myelosuppression
- Nausea and vomiting
- Alopecia
- Nephrotoxicity
- Neurotoxicity (encephalopathy)
Key clinical trials
- Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma (PHASE1)
- TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies (PHASE2)
- Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma (PHASE3)
- A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT (PHASE2)
- Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCL (NA)
- Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma (PHASE2)
- A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma (PHASE1, PHASE2)
- Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |